(BBLG) Bone Biologics - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US0980703039
BBLG: Protein, Bone Graft, Surgical Implants, Medical Devices
Bone Biologics Corporation (NASDAQ:BBLG) is a medical device company specializing in bone regeneration technologies, primarily targeting spinal fusion applications. The companys lead product, NELL-1/DBM, is an osteopromotive recombinant protein designed to enhance bone regeneration with precise control. This technology is central to the development of the NELL-1/DBM Fusion Device, intended for use in spinal fusion procedures in skeletally mature patients with degenerative disc disease affecting the L2-S1 spinal segments. Beyond spinal applications, the platform technology has potential utility across surgical specialties, including orthopedics, neurosurgery, and sports medicine.
Bone Biologics holds a license agreement with the UCLA Technology Development Group to commercialize NELL-1 for spinal fusion applications, underscoring its collaborative approach to innovation. Founded in 2004 and headquartered in Burlington, Massachusetts, the company operates in a niche segment of the medical device industry focused on addressing unmet needs in bone repair and regeneration.
3-Month Forecast: Based on
Additional Sources for BBLG Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
BBLG Stock Overview
Market Cap in USD | 3m |
Sector | Healthcare |
Industry | Medical Devices |
GiC Sub-Industry | Health Care Equipment |
IPO / Inception | 2016-03-31 |
BBLG Stock Ratings
Growth 5y | -77.8% |
Fundamental | -8.36% |
Dividend | 0.0% |
Rel. Strength Industry | -67.7 |
Analysts | 5/5 |
Fair Price Momentum | 0.75 USD |
Fair Price DCF | - |
BBLG Dividends
No Dividends PaidBBLG Growth Ratios
Growth Correlation 3m | -46.6% |
Growth Correlation 12m | -71.4% |
Growth Correlation 5y | -98.8% |
CAGR 5y | -90.03% |
CAGR/Max DD 5y | -0.90 |
Sharpe Ratio 12m | -1.40 |
Alpha | -75.37 |
Beta | 0.83 |
Volatility | 156.94% |
Current Volume | 18.1k |
Average Volume 20d | 95.4k |
As of March 14, 2025, the stock is trading at USD 0.83 with a total of 18,147 shares traded.
Over the past week, the price has changed by -1.52%, over one month by -19.68%, over three months by -26.13% and over the past year by -67.81%.
Neither. Based on ValueRay Fundamental Analyses, Bone Biologics is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -8.36 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of BBLG as of March 2025 is 0.75. This means that BBLG is currently overvalued and has a potential downside of -9.64%.
Bone Biologics has received a consensus analysts rating of 5.00. Therefor, it is recommend to buy BBLG.
- Strong Buy: 1
- Buy: 0
- Hold: 0
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, BBLG Bone Biologics will be worth about 0.8 in March 2026. The stock is currently trading at 0.83. This means that the stock has a potential upside of +1.2%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 16.5 | 1888% |
Analysts Target Price | 37.8 | 4448.2% |
ValueRay Target Price | 0.8 | 1.2% |